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A B S T R A C T
A 51-year-old man developed symptoms (palpitations) related to a large left atrial mass attached to
interatrial septum discovered by trans-thoracic heart ultrasonography. Six months earlier this patient
had undergone radiofrequency ablation (RFA) of an atrial ﬂutter substrate. The left atrial mass was
removed surgically using cardiopulmonary bypass with disappearance of symptoms. A post-operative
diagnosis of atrial myxoma was made. The present case shows that a big left-atrial tumor could manifest
with only mild unspeciﬁc symptoms such as palpitations. It is not clear whether the development of
myxomas could be related to RFA or occurrence of heart tumors after RFA (already reported in medical
literature) or whether it could be just chance without a causal link with ablation procedures.
<Learning objective: It is essential to consider myxoma in the differential diagnosis of cardiac masses
identiﬁed in patients after radiofrequency ablation since some cases of myxoma development after
radiofrequency ablation have recently been described in the literature. Transthoracic echocardiography is a
precise technique in the evaluation of cardiac masses, but a high index of clinical suspicion is necessary in
order to deﬁne intracardiac pathologies that could be missed for unspeciﬁc symptoms of presentation.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Primary tumors of the heart are not common: their incidence
has been estimated from 0.0017% to 0.19% in autopsy studies
performed in groups of unselected subjects. Myxoma is the most
frequent cardiac tumor, representing about 50% of all benign
neoplasms of the heart [1]. At present its incidence after
radiofrequency ablation (RFA) of an arrhythmic substrate is not
well known but some cases have been recently reported [2–6].
We describe the case of a quickly growing cardiac myxoma that
developed in the left atrium of a patient with persisting
palpitations after procedure of RFA for an atrial ﬂutter.
Case report
In February 2014, a 51-year-old man was referred to the
cardiology out-patient department of our institute (INRCA Fermo,
Italy), with a 2-year history of palpitations in the absence of* Corresponding author at: UO Cardiologia Riabilitativa, INRCA Presidio
Ospedaliero di Ricerca di Fermo, Contrada Mossa, 63900 Fermo, FM, Italy.
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The patient was a smoker with clinical history of type 2 diabetes
mellitus on diet treatment and kidney stones. RFA of a common
atrial ﬂutter substrate had been performed 6 months earlier. In
particular during the intracardiac electrophysiology study burst
pacing (until 200 ms cycles) from proximal coronary sinus catheter
and low right atrial catheter induced typical counterclockwise
ﬂutter phases (tachycardia cycle: 260 ms). So the patient
underwent transcatheter radiofrequency (RF) energy application
(30–50 W, 60 8C, 120 s) on cavo-tricuspid isthmus obtaining block
of isthmus conduction (details shown in supplementary materials).
In the weeks following the RFA procedure the patient had only mild
reduction of palpitations. The patient’s familial history was
unremarkable. In June 2013, for an inconclusive ergometric test
he had undergone coronary angiography without evidence of
signiﬁcant coronary atherosclerotic disease.
His current medications were aspirin 100 mg daily and
bisoprolol 1.25 mg daily. The beta-blocker was prescribed by the
family physician 3 days before the visit, for symptomatic
supraventricular extrasystoles also repetitive in unsustained runs
evidenced by a Holter electrocardiogram.
On general examination, the patient looked to be a well-
nourished man, without dyspnea at rest and without cyanosis ands reserved.
Fig. 2. Aspect of the mass after surgical excision.
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temperature was 36.8 8C. Physical examination revealed a blood
pressure of 130/70 mmHg and a heart rate of 60 beats/min. Clinical
characteristics indicative of familial myxomas (such as Carney
complex or familial autosomal dominant syndrome) were
excluded. No signiﬁcant pathological marks were present on
heart, lung and abdominal examinations. During the visit the
patient showed the results of laboratory analysis made 1 week
before. There were no hematological and biochemical abnormali-
ties with the exception of a mild elevation of fasting plasma
glucose (119 mg/dL).
The electrocardiogram showed sinus rhythm, mean frontal QRS
vector at 608, rare and isolated atrial ectopic beats, normal duration
of PR interval and QRS complex, normal QT length, and pre-existing
negative T wave in V5–V6 leads.
Transthoracic echocardiography revealed a large mass in the
left atrium. Its dimension was about a 2.7 cm  4 cm in four
chambers apical view and 2.4 cm  4 cm in two chambers apical
view. The mass was attached to the interatrial septum by a broad
base, appearing with a smooth surface and presenting both
hyperechogenic and hypoechogenic foci in its context. The mass
was slightly mobile but did not interfere with mitral leaﬂet
dynamics during all heart cycles (Fig. 1).
The rest of the ultrasonography study showed evidence of mild
left ventricular hypertrophy, mild mitral regurgitation, a left
ventricular ejection fraction of 55% (by Simpson biplane method),
and mild left atrial dilation (antero-posterior diameter: 48 mm).
Surprisingly the patient had undergone 2-dimensional echo-
cardiographic study also at the time of RFA procedure (6 months
before), showing no intracardiac masses.
The patient started subcutaneous low molecular weight
heparin and was referred for surgical resection which was
performed 5 days later, with the assistance of standard cardiopul-
monary bypass. The excision of the mass was obtained along with
its septal attachment after exposing the left atrium. Macroscopic
examination showed the tumor as brownish solid mass which was
the size of a citrus fruit, with a smooth and gelatinous surface
(Fig. 2).
Microscopic analysis of tumor sections showed a myxoid
matrix with polygonal and star-shaped cells disposed in clusters
and small areas of hemorrhage and necrosis. The histological
aspect was consistent with an atrial myxoma.
After surgical excision of the neoplasm, the patient made a
postoperative recovery without complications. Four months later
(June 2014), he was in sinus rhythm and asymptomatic for
palpitations. A new transthoracic echocardiography revealed no
intracardiac mass.Fig. 1.
Four-chamber and two-chamber views on echocardiogram showing a
large mass attached to interatrial septum.Discussion
We herein reported the case of a large left atrial myxoma
discovered on heart ultrasonography in a patient with persisting
palpitations after an RFA procedure for an atrial ﬂutter substrate.
Due to its great dimensions we think it is improbable that the
neoplasm was present but not seen on the echocardiogram
performed in the RFA pre-procedural period. The eventual early
identiﬁcation of the neoplasm imposed the consideration of a rapid
excision. In fact as described in the present case, myxomas require
immediate surgical operation due to their risk of embolism or
cardiovascular complications, including sudden death.
RFA represents often the decisive treatment option for
symptomatic patients with arrhythmias but it is associated with
the risk of several complications including both thrombus and
endocarditis in atria. Echocardiographic features of the mass can
suggest the right diagnosis. In fact left atrial myxomas appear often
as masses attached to the interatrial septum in the area of the fossa
ovalis or, less frequently, to the lateral wall of the atrium.
Interestingly, even if several myxoma cases are found
incidentally on transthoracic echocardiography, there are few
papers of cases in which a cardiac myxoma has been discovered
after RFA. At present to our knowledge, ﬁve reports before have
described the appearance of an atrial myxoma after RFA (Table 1).
Similar to our report, in three cases an early onset of a myxoma
after RFA over a few months was highlighted while in two cases the
appearance of the tumor has been documented later in life (from
2 to 6 years after RFA) [2–6].
It is not well known whether myxoma development is just a
coincidence or if there is a correlation with the previous ablation.
Considering that cardiac myxoma cells may result from adult
developmental remnants subjected to mitogenic stimuli, surely we
can identify three factors associated with RFA procedures
potentially able to induce a myxoma’s growth: radiation, heart
tissue trauma, and RF-related heat energy.
First, it should be underlined that RFA procedures require often
protracted ﬂuoroscopy times. A study has suggested that the use of
radioscopy during RFA could determine a small increase in the
lifetime risk of developing neoplasms [7].
Second, heart trauma and subsequent local inﬂammation have
been hypothesized to cause myxoma development. In cases of
myxomas that developed after atrial septum trans-septal tech-
nique, the iatrogenic puncture could have acted as a stimulus for
the development of a reactive lesion. Subsequently, the local tissue
injury could have promoted cell proliferation in the endocardium.
Finally, it can be speculated that the heat energy of the ablation
may contribute to heart neoplasm development. This mechanism
Table 1 Case reports of myxomas developing after RFA procedures.
Author (year of
publication)
Estimated growth
rate of myxoma
Time to
neoplasm
detection
after RFA
Type of RFA procedure Myxoma location Reference
Ancona R (2009) 0.416 cm/month 6 months RFA for recurrent AF with
transeptal technique
Right atrium (lateral free wall) [3]
Sirin G (2012) Not well deﬁned for
the long time from
RFA to neoplasm
detection
2 years RFA maze including inferior vena
cava ablation for recurrent AF
during prosthetic mitral valve
replacement
Right atrium (interatrial septum) [2]
Piestrzeniewicz
K (2012)
Not well deﬁned for
the long time from
RFA to neoplasm
detection
6 years Ablation of pulmonary veins and
lower atrial isthmus for
recurrent AF
Left atrium (foramen ovale) [4]
Alvarez JR (2013) 0.66 cm/month 3 months RFA for recurrent AF with
transeptal technique and
isolation of pulmonary veins
Left atrium (interatrial septum) [5]
Kourkoveli P (2014) 0.12 cm/month 12 months RFA for recurrent AF with
pulmonary veins ablation
Left ventriculum (apex) [6]
Santillo E (2015) 0.66 cm/month 6 months RFA of cavo tricuspid isthmus for
recurrent atrial ﬂutter
Left atrium (interatrial septum) Present paper
AF, atrial ﬁbrillation; RFA, radiofrequency ablation.
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where heat energy is applied.
Moreover, the growth rate of myxomas detected early after RFA
appears faster than in all other cases. In fact, in a former
observation Walpot estimated that cardiac myxomas present
growth rates of 0.49 cm/month [8]. This rate is slightly lower than
in two cases diagnosed after RFA as shown in Table 1.
More rapid growth of myxomas identiﬁed early after RFA
procedures could be attributed to properties of heat energy of RF.
In fact, RF has shown the ability to upregulate human cell
proliferation and trigger expression of genes and enzymes. The
upregulation of inﬂammatory gene expression could induce cell
responses and a faster neoplasm development [9].
Interestingly, it has been demonstrated that quick growth of
myxomas is related principally to enlargement of the intercellular
matrix, more than to the increase of cellular elements [10]. Wheth-
er RFA procedures are also able to induce these changes remains to
be established.
Taken together, these observations suggest that, due to its
possible rapid growth, a myxoma should always be considered in
the differential diagnosis of new intracardiac mass in patients who
have previously undergone RFA, also in the presence of a recent
normal echocardiogram.
In summary, we reported the case of a man manifesting
unspeciﬁc symptoms related to left atrial myxoma that developed
6 months after RFA procedure. Causal links between RFA and
myxoma growth could be hypothesized but remain to be proven.
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